Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

suming that the sponsor follows the protocol agreed-upon with the Agency, the sponsor has provided appropriate information to the Agency to support the protocol, the sponsor and the Agency agree to modify the protocol or a substantial scientific issue is identified after clinical testing has begun. In the absence of these developments, "completion of a SPA with FDA provides binding agreement relative to design and analysis of key Phase 3 trial(s) such that positive final results can lead to full NDA/ BLA approval." For more information about the Agency's Special Protocol Assessment process, see, http://www.fda.gov/cder/guidance/3764fnl.htm.

About Tanespimycin

Tanespimycin has been shown to induce apoptosis of drug-sensitive and drug-resistant multiple myeloma cell lines. Tanespimycin also inhibits expression of various cell surface cytokines, such as IGF-1R and IL-6R, that are involved in growth, survival and drug resistance of multiple myeloma cells. When used in combination with bortezomib, the destabilization of client proteins with tanespimycin while blocking their degradation with bortezomib promotes the accumulation of cytotoxic proteins, leading to cell death.

Kosan reported data from a Phase 1b trial of tanespimycin in combination with bortezomib at the 2007 annual meeting of the American Society for Clinical Oncology (ASCO) on 56 patients enrolled in 7 dose cohorts (100-340 mg/m2 of tanespimycin; 0.7-1.3 mg/m2 of bortezomib; tanespimycin administered via 1-hour infusion following the bortezomib dose 2 times per week every 2 weeks out of 3 weeks). Of these 56 patients, all had received multiple prior chemotherapy regimens (median of 4) and 67% had received bone marrow transplants.

In those patients who received tanespimycin across the range of doses tested and a dose of 1.0 or 1.3 mg/m2 of bortezomib, the overall response rate including complete, partial and mini
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015   Mast ... biopharmaceutical company leveraging its molecular adhesion and sealant ... sickle cell disease, heart failure, and arterial disease, ... EPIC study of its lead product ... surpassed the halfway point. Consistent with prior guidance, ...
(Date:4/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5jt68c/global_api_market ) has ... 2018" report to their offering. Global API ... the Global API industry is expected to grow at a ... been divided into four major geographies which comprise Americas, ... the rest of the world. For every region, a current ...
(Date:4/21/2015)... MENLO PARK, Calif. , April 21, 2015 /PRNewswire/ ... company focused on the emerging field of regenerative medicine, ... patients with acute myelogenous leukemia (AML) from the Phase ... cell cancer vaccine, AST-VAC1, has been selected for an ... Oncology (ASCO) Annual Meeting, to be held in ...
Breaking Medicine Technology:Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 2Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 3Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 4Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 5Global API Market Outlook Report 2014-2018 2Global API Market Outlook Report 2014-2018 3Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting 2Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting 3
... , ... Albemarle Corporation (NYSE: ALB ), a leading global ... PharmaCore to provide manufacturing capabilities for customers with projects that require ... alliance allows a seamless technology transfer from PharmaCore to Albemarle ...
... , ... Systems, Inc. today announced full integration between AVImark veterinary software ... the two-way connection allows diagnostic test requisitions and patient data ... any AVImark workstation in a veterinary practice. Test results are ...
Cached Medicine Technology:Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R) 2Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R) 3Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R) 4Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R) 5McAllister Software Systems, Inc. and IDEXX Laboratories, Inc. Announce Availability of the IDEXX VetLab(R) Station InterLink(TM) Connection to AVImark(R) 2010 2McAllister Software Systems, Inc. and IDEXX Laboratories, Inc. Announce Availability of the IDEXX VetLab(R) Station InterLink(TM) Connection to AVImark(R) 2010 3McAllister Software Systems, Inc. and IDEXX Laboratories, Inc. Announce Availability of the IDEXX VetLab(R) Station InterLink(TM) Connection to AVImark(R) 2010 4
(Date:4/21/2015)... The American Society for Dermatologic Surgery is ... Brandt, M.D., by setting up two memorial funds in ... 1982, died earlier this month at age 65 at ... opportunities for ASDS members, industry and any interested donors ... Brandt held so dear. , “Dr. Brandt was one ...
(Date:4/21/2015)... 2015 NOVAtime Technology, Inc. ( ... and Attendance / Workforce Management solutions, announced its ... American Payroll Association (APA) as well as NetSuite’s ... has been the nation’s payroll authority since 1982, ... and recertification credits. Held at the MGA Grand ...
(Date:4/21/2015)... Saint Louis, MO (PRWEB) April 21, 2015 ... April 29, 2015 from 5:00 to 8:00 pm at the ... Center Drive, Chapel Hill, NC 27599. More than 50 hospitals, ... across the country. All specialties will be represented. Attendees will ... Thompson, Director of Career Fairs for PracticeMatch says ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Atlantic ... the launch of Medicare-Medicaid Dual Eligibles Database, a ... on care provided to the more than 9 ... account for more than $300 billion in annual ... – the same team that also creates the ...
(Date:4/21/2015)... eSight is the only technology in the world that helps ... May 5th, Low Vision Specialists of Maryland and Virginia ... unveiling and demonstration of the technology at 8:30 a.m at ... be the first ophthalmic practice in Maryland to offer the ... be available on the day of the unveiling. , How ...
Breaking Medicine News(10 mins):Health News:ASDS honors the legacy of Dr. Fredric Brandt 2Health News:ASDS honors the legacy of Dr. Fredric Brandt 3Health News:ASDS honors the legacy of Dr. Fredric Brandt 4Health News:NOVAtime Participates in 2015 APA Congress and NetSuite SuiteWorld Conferences in May 2Health News:NOVAtime Participates in 2015 APA Congress and NetSuite SuiteWorld Conferences in May 3Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 2Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 3Health News:New AIS Database Tracks All Programs, Plans Serving the Dual-Eligible Community 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 3
... Study Reveals the Most Common Reasons Why Total Hip ... thousands of patients undergo total hip replacement surgery in ... disease and other related hip problems. According to ... of The Journal of Bone and Joint Surgery ...
... Jan. 2 Joan Lunden, the nation,s,longest-running morning ... two decades. During her tenure she reported ... two Royal weddings. One of the most,visible ... of her career to,educating Americans about health and ...
... ATLANTA, Jan. 2 Publix, Procter & Gamble, and,Special ... people with,intellectual disabilities achieve their dreams. Now they,re ... Special Olympics. , 1. Support ... by,purchasing your favorite P&G products like Tide, Pampers, Bounty ...
... tips on how to avoid injury while performing winter ... snow from your driveway and sidewalks can be physically ... proper health and safety precautions, says the American Academy ... than 118,000 people were treated in U.S. hospital emergency ...
... keep colds and flu at bay , , FRIDAY, Jan. 2 ... there,s one tidbit that doctors stand by as the best way ... free of germs is one of the simplest and most effective ... other infectious disease, experts say. , "Disease transmission is hand-to-hand combat, ...
... Va.In a study to determine the diagnostic value of ... cancer, researchers were able for the first time to ... and normal residual thyroid tissue directly after surgery. , ... an article in the January issue of The ...
Cached Medicine News:Health News:Replacing Your Total Hip Replacement 2Health News:Replacing Your Total Hip Replacement 3Health News:Joan Lunden Inks Three-Year Deal to Host Health Corner(R) Television Series 2Health News:'Be A Fan' of Special Olympics Throughout January 2Health News:Shovel Snow Safely 2Health News:To Protect Yourself, Wash Those Germs Away 2Health News:To Protect Yourself, Wash Those Germs Away 3Health News:To Protect Yourself, Wash Those Germs Away 4Health News:Molecular imaging enables earlier, individualized treatment of thyroid cancer 2
The DuraSeal System includes an innovative polyethylene glycol hydrogel sealant and applicator packaged in a single-use kit which can be stored at room temperature for convenience and quick preparati...
Mastisol Liquid Adhesive is a clear, non-irritating, and non-water-soluble liquid adhesive that secures the most difficult dressings for an extended period of time. Mastisol is 7 to 10 times stickier...
GluStitch® is indicated for the closure of uncomplicated skin lacerations where there is little or no tissue loss....
... GE Healthcare is ... in best-in-class analysis programs ... area monitoring device. With ... 12SL, Gender-Specific, and ACI-TIPI, ...
Medicine Products: